Associate Professor, Internal Medicine, Washington University School of Medicine
Oncology
Dr. Katherine N. Weilbaecher, MD
|
|
Give Review
Katherine Weilbaecher practices Oncology. He attended Stanford University School of Medicine. Stanford University School of Medicine is a top medical university. Stanford University School of Medicine is ranked 2 in research and 25 in primary care medicine He over the years received 1 awards: "Elected Member". Dr. Katherine N. Weilbaecher is a published doctor and has 28 publications published. The lastest was: 'Dual-therapy with v3-targeted Sn2 lipase-labile Fumagillin-prodrug Nanoparticles and Zoledronic Acid in the Vx2 Rabbit Tumor Model.' He is registered with Medicare and accepts Medicare payments.
Publications
- CXCR4 Protein Epitope Mimetic Antagonist POL5551 Disrupts Metastasis and Enhances Chemotherapy Effect in Triple-Negative Breast Cancer.
- Dual-therapy with αvβ3-targeted Sn2 lipase-laBile Fumagillin-prodrug Nanoparticles and Zoledronic Acid in the Vx2 Rabbit Tumor Model.
- Thrombospondin-1 Regulates Bone Homeostasis Through Effects on Bone Matrix Integrity and Nitric Oxide Signaling In Osteoclasts.
- Acute Depletion of Endothelial β3-Integrin Transiently Inhibits Tumor Growth and Angiogenesis in Mice.
- A Randomized Phase II Trial Investigating the Effect of Platelet Function Inhibition on Circulating Tumor Cells in Patients With Metastatic Breast Cancer.
- Noncompetitive Modulation of the Proteasome by Imidazoline Scaffolds Overcomes Bortezomib Resistance and Delays MM Tumor Growth in Vivo.
- Very Late Antigen-4 (?(4)?(1) Integrin) Targeted PET Imaging of Multiple Myeloma.
- The epoxyketone-based proteasome inhibitors carfilzomib and orally bioavailable oprozomib have anti-resorptive and bone-anabolic activity in addition to anti-Myeloma e...
- Role of WNT7B-induced non-canonical pathway in advanced prostate Cancer.
- Antagonism of Inhibitor of Apoptosis Proteins Increases Bone Metastasis via Unexpected Osteoclast Activation.
- Integrin ?(v)? (3) as a PET Imaging Biomarker for Osteoclast Number in Mouse Models of Negative and Positive Osteoclast Regulation.
- Integrins and bone metastasis: integrating tumor cell and stromal cell interactions.
- Dissection of platelet and myeloid cell defects by conditional targeting of the beta3-integrin subunit.
- The ARF tumor suppressor regulates bone remodeling and osteosarcoma development in mice.
- Targeting the alphavbeta3 integrin for Small-animal PET/CT of osteolytic bone metastases.
- CD47 regulates bone mass and tumor metastasis to bone.
- Interferon-gamma targets Cancer cells and osteoclasts to prevent tumor-associated bone loss and bone metastases.
- Advancing treatment for metastatic bone Cancer: consensus recommendations from the Second Cambridge Conference.
- RelB is the NF-kappaB subunit downstream of NIK responsible for osteoclast differentiation.
- Isolation and molecular profiling of bone marrow micrometastases identifies TWIST1 as a marker of early tumor relapse in breast Cancer patients.
- Disruption of CXCR4 enhances osteoclastogenesis and tumor growth in bone.
- Noninvasive imaging of osteoclasts in parathyroid hormone-induced osteolysis using a 64Cu-labeled RGD peptide.
- Advances in treating metastatic bone Cancer: summary statement for the First Cambridge Conference.
- Platelet and osteoclast beta3 integrins are critical for bone metastasis.
- Comparison of five antibodies as markers in the diagnosis of melanoma in cytologic preparations.
- The melanocyte-specific isoform of the microphthalmia transcription factor affects the phenotype of human melanoma.
- Role for microphthalmia transcription factor in the diagnosis of metastatic malignant melanoma.
Schools
Stanford University
Stanford University Hospital
Dana Farber Cancer Institute
Procedures Preformed
- Thoracentesis
Conditions Treated
- Anal and Rectal Cancer
- Anemia
- Bile Duct Cancer
- Brain and Nervous System Cancer (incl. Gliomas, Astrocytoma, Schwannoma, Medulloblastoma, Chordoma)
- View All
Doctors Specialties
- Medical Oncology
- Oncology
Accepted Insurances
- Aetna HMO
- Choice Plus POS II
- Anthem Blue Cross Blue Shield PPO
- Blue Card PPO
- Blue Cross Blue Shield of Illinois PPO
- Cigna HMO
- Cigna PPO
- Great West Healthcare-Cigna PPO
- LocalPlus
- Open Access Plus
- Coventry Health Care of Kansas, Inc. PPO
- Coventry Health Care of Missouri PPO
- First Health (Coventry Health Care) PPO
- HealthLink PPO
- Homestate Health Plan
- Choice Care PPO
- Medicare MCR
- MultiPlan PPO
- PHCS Network PPO
- Choice Plus POS
- Navigate HMO
- Navigate POS
- Options PPO
- United Healthcare
Awards
- Elected Member
Education
-
Brigham and Women's Hospital -
Stanford University -
Stanford University School of Medicine
Hospital
-
Barnes-Jewish Hospital
Helpful Reviews
Medicare Facts
| National Provider Identifier [NPI] | 1447277942 |
| Last Name Of The Provider | WEILBAECHER |
| First Name Of The Provider | KATHERINE |
| View All |
Similar Doctors
|
|
Dr. Eric M. Knoche, MD
 This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Timothy P. Rearden, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Peter Westervelt, MD
This Doctor is OpenDoctor Recommended.
 This doctor has more publications
|
|
|
Dr. Steven M. Pincus, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Bethany G. Sleckman, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Yee H. Chia, MD |
|
|
Dr. Vorachart Auethavekiat, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Amanda Cashen, MD
This Doctor is OpenDoctor Recommended.
This doctor has more publications
|
|
|
Dr. Steven M. Sorscher, MD
This Doctor is OpenDoctor Recommended.
This doctor has more publications
|
|
|
Dr. Geoffrey L. Uy, MD
This Doctor is OpenDoctor Recommended.
This doctor has more publications
|
|
|
Dr. Timothy A. Graubert, MD
This Doctor is OpenDoctor Recommended.
This doctor has more publications
|
|
|
Dr. Maria Q. Baggstrom, MD
This Doctor is OpenDoctor Recommended.
|